Last reviewed · How we verify

NCT04074824

A Genome-Wide Association Study for Neonatal Diseases

Active, enrolled Last updated 18 June 2025
What this trial tests

trial in Neonatal Disease in 310 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
1 September 2018
Primary endpoint
31 October 2026
31 October 2026

Quick facts

Lead sponsorChinese University of Hong Kong
StatusActive, enrolled
Study typeOBSERVATIONAL
Enrollment310
Start date1 September 2018
Primary completion31 October 2026
Estimated completion31 October 2026
Sites1 location across Hong Kong

Conditions studied

Sponsor

Chinese University of Hong Kong

Who can join

Eligibility, any sex, with Neonatal Disease or Necrotizing Enterocolitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an observational study to identify genetic risks for neonatal diseases, necrotizing enterocolitis (NEC) using genome-wide association study (GWAS) and enterotype investigation. We hypothesize that specific genetic factors and microbiome could predispose preterm neonates for the development of NEC.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Neonatal Disease

Currently open trials in the same condition.

Other Chinese University of Hong Kong trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04074824.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing